Clinical Pharmacology of RNA Interference–Based Therapeutics: A Summary Based on Food and Drug Administration–Approved Small Interfering RNAs
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Pharmacology of RNA Interference–Based Therapeutics: A Summary Based on Food and Drug Administration–Approved Small Interfering RNAs
Authors
Keywords
-
Journal
DRUG METABOLISM AND DISPOSITION
Volume 51, Issue 2, Pages 193-198
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Online
2022-11-04
DOI
10.1124/dmd.122.001107
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Strategies for improving the safety and RNAi efficacy of noncovalent peptide/siRNA nanocomplexes
- (2022) Jun Wang et al. ADVANCES IN COLLOID AND INTERFACE SCIENCE
- Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported
- (2022) Sander Bins et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Proteolysis-targeting chimeras (PROTACs) in cancer therapy
- (2022) Xinyi Li et al. Molecular Cancer
- Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview
- (2022) Jae Yoon Jeon et al. PHARMACEUTICAL RESEARCH
- siRNA Drugs: Here to Stay
- (2021) John J. Rossi et al. MOLECULAR THERAPY
- Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges
- (2021) Kiara Fairman et al. BIOCHEMICAL PHARMACOLOGY
- A Drug‐Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid (siRNA), on Cytochrome P450 Activity in Liver
- (2021) Daphne Vassiliou et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Nonclinical Disposition and PK/PD Properties of GalNAc-conjugated siRNA Are Highly Predictable and Build Confidence in Translation to Man
- (2021) Robin McDougall et al. DRUG METABOLISM AND DISPOSITION
- The current landscape of nucleic acid therapeutics
- (2021) Jayesh A. Kulkarni et al. Nature Nanotechnology
- Antibody–oligonucleotide conjugates enter the clinic
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
- (2020) Sarah Bajan et al. Cells
- Advances with RNAi-Based Therapy for Hepatitis B Virus Infection
- (2020) Fiona van den Berg et al. Viruses-Basel
- Paving the Road for RNA Therapeutics
- (2020) Niels Dammes et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012‐2018
- (2020) Hobart Rogers et al. CTS-Clinical and Translational Science
- In Vitro Drug-Drug Interaction Evaluation of GalNAc conjugated siRNAs Against CYP450 Enzymes and Transporters
- (2019) Diane Ramsden et al. DRUG METABOLISM AND DISPOSITION
- Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
- (2018) Jennifer L.S. Willoughby et al. MOLECULAR THERAPY
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
- (2018) Aaron D. Springer et al. Nucleic Acid Therapeutics
- CRISPR-Cas guides the future of genetic engineering
- (2018) Gavin J. Knott et al. SCIENCE
- The delivery of therapeutic oligonucleotides
- (2016) Rudolph L. Juliano NUCLEIC ACIDS RESEARCH
- Pharmacokinetic Behaviors of Intravenously Administered siRNA in Glandular Tissues
- (2016) Yuanyu Huang et al. Theranostics
- Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention
- (2015) Dominik Witzigmann et al. HEPATOLOGY RESEARCH
- siRNA Versus miRNA as Therapeutics for Gene Silencing
- (2015) Jenny K W Lam et al. Molecular Therapy-Nucleic Acids
- Molecular Mechanisms of RNA Interference
- (2013) Ross C. Wilson et al. Annual Review of Biophysics
- History of gene therapy
- (2013) Thomas Wirth et al. GENE
- Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
- (2012) Rosemary L Kanasty et al. MOLECULAR THERAPY
- siRNA Off-Target Effects Can Be Reduced at Concentrations That Match Their Individual Potency
- (2011) Daniel R. Caffrey et al. PLoS One
- Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
- (2009) Aimee L. Jackson et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started